DR REDDYS LABORATORIES LTD — Capital/Financing Update 2021

Mar 31, 2021

Dr. Reddy1s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad· 500 034, Telangana, India. CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

March 31, 2021

To, The Secretary BSE Limited National Stock Exchange of lndia Ltd. New York Stock Exchange Inc. NSE IFSC Limited

Dear Sir/ Madam,

Sub: Agrccm ·111 lo conl1ih11lr to All :o Tt•chnolou,irs LLl

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has entered into a partnership agreement with ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure-A.

This is for your information and record.

Thanking you,

Yours faithfully,

For Dr. Reddy's Laboratories Limited SANDEEP =':';:!;,.-- "' - PODDAR �-- ::.�-:ri:-=:-:.�-· .. -- Sandeep Poddar

Company Secretary

Encl: As above

Annexurc A

a)Name of the target entity, details in briefsuch as size, turnover etc.b)Whether the acquisition would fallwithin related party transaction(s) andwhetherthepromoter/promotergroup/group companies have any interestin the entity being acquired? If yes, nature	i) Name of the Target entity: ABCDTechnologies LLP (to be renamed asIndoHealth Services LLP).ii)Details of Target entity: The targetentity 1s a newly incorporated limitedliability partnership ('LLP') and has notcommenced any business activities.--- ----JNo
of interest and details thereof and whetherthe same is done at "arms-length"
c)Industry to which the entity beingacquired belongs	Chain-Healthcare/DigitalSupplyPharmaceuticalandalliedsegments/services.
d)Objectsand effectsof acquisition(including but not limited to, disclosure ofreasons for acquisition of target entity, ifitsbusiness is outside the mainline ofbusiness of the listed entity	Thetransaction1smlinewiththeCompany's purpose of accelerating accessand affordability of medicines to all, andthestrategyofleveragingdigitaltechnology and infrastructure towards this.The proposed business of Target entity willbe carried out with an objective to facilitatethedigitizationofthehealthcareinfrastructuremIndiatowardsenhancementofGoodDistributionPractices ("GDP") inter alia, in support ofthe National Digital Health Mission ofGovernment of India ("Business.").
e)Brief details of any governmental orregulatory approvalsrequiredfortheacquisition	None
Indicative time period for completion of March 31, 2021.f)the acquisition	Subsequent tranches of contribution willfollow basis the contribution made byother partners. -------------'

Dig ii.ally signed by SAN DEEP POD DAR Df'l:(.r.,IIN111d1mnN� 8c9d\lffOt:.tw.Mc54-hCI. 2.5.4JO,.b!un�,J.,itdc5�7,11�1at7 Ob9SOSd6d:i1idl4al,(t(IMJe11)0(d73e ..ii:a66tl..,CJ�c334f5ebc1a1790e158f29 af33bf2Qlkac, cn=SANDEEP PODDAR Dale: 2021033114:07:53 +05'30'

Dr. Reddy's

ò,

g) Nature of consideration – whether cash $\parallel$consideration or share swap and details ofthe same	Cash infusion as capital contributionand/or loan.
h) Cost of acquisition or the price at which	ContributionINR40uptocrores
the shares are acquired	corresponding to the contribution by the
	other partners.
	The overall contribution is scalable over a
	period of time with the same share of
	profit/losscorrespondingthe$\iota$
	contribution of other partners.
i) Percentage of shareholding / control	Upto 20% share of profit/loss in LLP.
acquired and/or number of shares acquired
j) Brief background about the entity	The target entity has been incorporated on
acquired in terms of products/line of	February 10, 2021 with an object to
business acquired, date of incorporation,	facilitate, enable and promote efficiency in
history of last 3 years turnover, country in	pharma supply chain and larger pharma
which the acquired entity has presence and	ecosystem to enable the stakeholders to
any other significant information (in brief)	provide better and more affordable patient
	care solutions, in line with the objectives of
	NDHMwithstrictlyactivitiesin
	compliance with applicable law.
	The LLP will be an industry digital
	initiative by certain major pharmaceutical
	companies.
	The Target entity will be a holding entity
	and would undertake business through one
	more LLPs or subsidiaries.

$\begin{array}{l|l|l|} \hline & \text{Digitally signed by SANDEEP PODOAR} \\hline \textbf{SAND} & \textbf{P1} & \textbf{P1} & \textbf{O1} & \textbf{O1} & \textbf{O1} & \textbf{O1} \\hline \textbf{P1} & \textbf{P1} & \textbf{O1} & \textbf{O1} & \textbf{O1} & \textbf{O1} \\hline \textbf{P2} & \textbf{P3} & \textbf{O1} & \textbf{O1} & \textbf{O1} & \textbf{O1} & \textbf{O1} \\hline \textbf{P3} & \textbf{O1} &$